Patents Assigned to Qiagen Marseille SA
  • ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS
    Publication number: 20190323085
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: February 28, 2019
    Publication date: October 24, 2019
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: Véronique Gelsi-Boyer, Daniel Birnbaum
  • ASXL1 AS A NEW DIAGNOSTIC MARKER OF MYELOID NEOPLASMS
    Publication number: 20150125868
    Abstract: The present invention relates to a method for diagnosing a myeloid cancer in a subject, which comprises the step of analyzing a biological sample from said subject by determining the presence or the absence of a mutation in the ASXL1 (additional sex combs like 1) gene coding for the polypeptide having the sequence SEQ ID No 2. A kit for diagnosing myeloid cancer in a subject comprising at least one nucleic acid probe or oligonucleotide or at least one antibody, which can be used in a such a method.
    Type: Application
    Filed: October 10, 2014
    Publication date: May 7, 2015
    Applicants: Qiagen Marseille SA, Institut Paoli-Calmettes, INSERM (Institut National de la Santé et de la Recherche Médicale)
    Inventors: VÉRONIQUE GELSI-BOYER, DANIEL BIRNBAUM